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Bacillus anthracis is reported to be naturally resistant to trimethoprim (TMP), a drug that inhibits dihy-
drofolate reductase (DHFR), a key enzyme in the folate pathway. A microdilution broth assay established that
the MIC of TMP for B. anthracis Sterne is >2,048 but<4,096 g/ml. A putative DHFR sequence was amplified
from B. anthracis Sterne genomic DNA. The PCR product was cloned into the Invitrogen pCRT7/CT-TOPO
vector, followed by transformation into Escherichia coli TOP10F chemically competent cells. Plasmid DNA
from a clone showing the correct construct with a thrombin cleavage site attached downstream from the
terminus of the cloned PCR product was transformed into E. coli BL21 Star (DE3)pLysS competent cells for
expression of the six-histidine-tagged fusion protein and purification on a His-Bind resin column. Function-
ality of the purified Sterne recombinant DHFR (Sterne rDHFR) was confirmed in an established enzyme assay.
The 50% inhibitory concentrations of TMP and methotrexate for the Sterne rDHFR were found to be 77,233
and 12.2 nM, respectively. TMP resistance was observed with E. coli BL21 Star (DE3)pLysS competent cells
transformed with the Sterne DHFR gene. Alignment of the amino acid sequence of the Sterne DHFR gene
revealed 100% homology with various virulent strains of B. anthracis. These results confirm the natural
resistance of B. anthracis to TMP and clarify that the resistance is correlated to a lack of selectivity for the
chromosomally encoded gene product. These findings will assist in the development of narrow-spectrum
antimicrobial agents for treatment of anthrax.
With the increased threat of bioterrorism, it is apparent that
the development of new and/or improved antimicrobial agents is
a critical and logical response to the hazards that could result
from an attack with biological agents. It is important to develop
new therapeutics in such a way as to expedite clinical trials and
subsequent availability for biodefense. One biological weapon
that poses a major threat is the spore-forming gram-positive bac-
terium Bacillus anthracis, the etiological agent of anthrax.
One of the priorities of the National Institute of Allergy and
Infectious Diseases division of the National Institutes of
Health (NIH) is the design, development, and testing of prod-
ucts specific to category A to C priority pathogens. Bacillus
anthracis is on the list of category A priority pathogens. One of
the objectives of NIH is to develop narrow-spectrum antimi-
crobial agents for use in the treatment of anthrax.
At this time, three types of antibiotics are approved for
treatment of anthrax, ciprofloxacin (a quinolone), tetracyclines
(including doxycycline), and penicillins (14). Increasing resistance
to quinolones and macrolides can develop in B. anthracis (3), and
doxycycline-resistant strains of B. anthacis have been genetically
engineered (25). Penicillin-resistant strains have also been iden-
tified (4, 6, 18). Some of these strains were negative for beta-
lactamase production (6), whereas some were not (18). Two an-
timicrobial agents generally used in combination that are not
recommended at this time are trimethoprim (TMP) and sulfame-
thoxazole (14). The justification for this appears to have resulted
from findings reported in a 1991 article that described the anti-
biotic sensitivity patterns of B. anthracis strains that were isolated
from the Kruger National Park in South Africa (20). In that
report, 44 B. anthracis isolates from animal carcasses and soil in
various locations of an area where anthrax is endemic were tested
for susceptibility to 18 different antibiotics (20). Using a standard
disk diffusion method, the team observed resistance to TMP and
sulfamethoxazole in 100% of the isolates (20). Resistance to
TMP-sulfamethoxazole has been reported in at least one other
study involving B. anthracis isolated from cutaneous anthrax cases
in an area of Turkey where anthrax is endemic (2). Trimethoprim
and sulfamethoxazole are antimicrobial agents that inhibit dihy-
drofolate reductase (DHFR) and dihydropteroate synthase, re-
spectively, two key enzymes in the folate biosynthetic pathway
that generates cofactors necessary for continued DNA and RNA
synthesis.
The objectives of this study were to (i) verify the TMP
resistance identified in the previous study for B. anthracis, (ii)
clone and express the chromosomally encoded DHFR gene
from the B. anthracis Sterne strain, (iii) confirm its function-
ality in an appropriate enzyme assay, and (iv) verify its resis-
tance to TMP. With that information and the recombinant
enzyme, it would then be possible to establish effective drug
screening that could be used to search for effective DHFR
inhibitors. The ultimate aim of this work is to exploit the
natural resistance pattern in B. anthracis and use it to develop
narrow-spectrum antibiotics for treatment of anthrax.
(Part of this research was presented at the American Society
for Microbiology Biodefense Research Meeting in March 2004
[abstract 165].)
MATERIALS AND METHODS
In vitro drug susceptibility. Using commercially available disks (Sensi-Disk;
Becton Dickinson), B. anthracis Sterne, and Escherichia coli (ATCC 25922;
positive control) were screened against trimethoprim (TMP) (5 g), sulfame-
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thoxazole-trimethoprim (SXT) (23.75 g of sulfamethoxazole and 1.25 g of
trimethoprim), and sulfisoxazole (250 g). The screening results indicated that B.
anthracis Sterne strain was resistant to TMP (5 g), resistant to SXT, and
sensitive to sulfisoxazole. E. coli zones were the appropriate size and fell within
NCCLS guidelines (data not shown).
Subsequently, the MIC of TMP for B. anthracis Sterne was determined by an
AlamarBlue microdilution broth assay modified from a previously described
method (26). Ninety-six-well microtiter panels of test compounds and control
antimicrobial agents were prepared according to the NCCLS broth microdilution
reference method in cation-adjusted Mueller-Hinton broth (CAMHB) (Becton
Dickinson) containing 10% AlamarBlue dye reagent (TREK Diagnostic Sys-
tems) (19).
B. anthracis Sterne was subcultured twice on Trypticase soy agar (TSA) plates
containing 5% sheep blood (Hardy Diagnostics). Cultures were incubated at
35°C overnight. Bacteria were transferred to 5 ml of sterile saline and suspended
to a turbidity of a 0.5 McFarland standard. From the suspension, a 1:20 dilution
was made in CAMHB, and 10 l was inoculated into each test well in a 96-well
plate (19). Microdilution panels were then placed into a gas-diffusible polypro-
pylene bag in ambient air at 35°C for 16 to 20 h. The number of CFU in the final
inoculum was verified by inoculating appropriate dilutions onto TSA blood agar
plates and counting the colonies. The final inoculum was approximately 7.5 105
CFU/ml or 7.5  104 CFU/100-l well, as suggested by NCCLS (19). Quality
control bacterial strains were tested against antimicrobial agents for which ac-
ceptable ranges have been published (19).
Quality control drugs were prepared at appropriate concentrations in
CAMHB and then aliquoted into 96-well plates at 100 l/well (plate 1). For B.
anthracis Sterne, the following group of drugs, at twofold dilutions, were used: (i)
TMP at 0.25, 0.50, 1.0, 2.0, 4.0, 8.0, 16.0, and 32.0 g/ml, (ii) doxycycline at 0.25,
0.5, 1.0, 2.0, 4.0, and 8.0 g/ml, and (iii) ciprofloxacin at 0.125, 0.25, 0.5, 1.0, 2.0,
and 4.0 g/ml. These drugs and concentrations are based upon NCCLS inter-
pretive standards for B. anthracis (Table 2K in reference 19): 1.0 g/ml for
doxycycline and  0.5 g/ml for ciprofloxacin. These three drugs and the com-
plete range of twofold dilutions were set up in duplicate in a 96-well plate, in
addition to growth and sterility controls. A standardized inoculum of B. anthracis
Sterne was prepared as described above, and 10 l was used to inoculate each
well, except the wells reserved for sterility control. Plates were incubated at 35°C
for 16 to 20 h. Controls were set up on all 96-well panels used in this study.
To validate antibiotic performance on each plate, wells were set up with the
following quality control strains: E. coli ATCC 25922 for doxycycline (twofold
dilution range, 0.25 to 8.0 g/ml) and for TMP from 0.25 to 32 g/ml; Staphy-
lococcus aureus ATCC 29213 for TMP (twofold dilution range, 0.25 to 32.0
g/ml) and ciprofloxacin (twofold dilution range, 0.125 to 4.0 g/ml); and En-
terococcus faecalis ATCC 29212 for ciprofloxacin from 0.125 to 4.0 g/ml and for
TMP from 0.25 to 32.0 g/ml. A standardized inoculum was prepared for each
organism in the same manner as inoculum for test strains and used to inoculate
appropriate wells. Plates were incubated at 35°C for 16 to 20 h.
After incubation, the MIC was read visually and in an optical microtiter plate
reader programmed to subtract the absorbance at 600 nm (A600) from that at 570
nm (A570). The MIC is reported as the lowest drug concentration yielding a
differential absorbance of zero or less (i.e., color remains blue). MICs were
compared to acceptable limits for quality control strains (Table 3 in reference 19)
to validate drug performance.
All quality control tests were within expected ranges, but B. anthracis Sterne
was not inhibited by TMP at 32.0 g/ml. As a result, the 96-well format was
redesigned to encompass higher concentrations of TMP; twofold dilutions were
used from 48 to 2,048 g/ml. After 16 h, the growth of B. anthracis Sterne was
reduced by 2,048 g of TMP per ml, but by 20 h, these wells showed growth using
the microtiter plate reader. The 96-well plate format was again designed to
include higher levels of TMP for testing against B. anthracis Sterne; twofold
dilutions up to 8,192 g of TMP per ml were included in addition to the lower
dilutions previously used. Drugs at these higher concentrations precipitated out
of solution during incubation. In order to achieve these drug concentrations, the
amount of dimethyl sulfoxide was increased to a level that showed growth
inhibition with the solvent control. After 20 h of incubation at 4,096 g of TMP
per ml, there was a differential absorbance reading (A570  A600) of 0.116, while
the solvent control differential was 0.943.
Transfer of resistance to E. coli. In vitro susceptibility was also determined for
E. coli BL21 Star (DE3)pLysS chemically competent cells. E. coli BL21 Star
(DE3)pLysS chemically competent cells were transformed with the Invitrogen
pCRT7/CT-TOPO vector (Invitrogen Life Technologies) or the Invitrogen
pCRT7/CT-TOPO vector with the B. anthracis Sterne DHFR insert (pCRT7/
CT-TOPO-Sterne DHFR). E. coli BL21 Star (DE3)pLysS was grown on Luria-
Bertani (LB) agar containing 34 g of chloramphenicol per ml. E. coli BL21 Star
(DE3)pLysS, carrying either pCRT7/CT-TOPO or pCRT7/CT-TOPO-Sterne
DHFR, was grown on LB agar medium containing 34 g of chloramphenicol per
ml and 100 g of carbenicillin per ml. The same protocol used to set up the MIC
plate for B. anthracis Sterne was used with the E. coli strains with the following
modifications. All saline and CAMHB used for E. coli BL21 Star (DE3)pLysS
had 34 g of chloramphenicol per ml added. All saline and CAMHB used for E.
coli BL21 Star (DE3) carrying pLysS and pCRT7/CT-TOPO-Sterne DHFR had
34 g of chloramphenicol per ml and 100 g of carbenicillin per ml added. TMP
was used in twofold serial dilutions from 1 to 4,096 g/ml. E. coli (ATCC 29522)
and Enterococcus faecalis (ATCC 29212), control organisms, were tested against
TMP, doxycycline, and SXT. Inoculum preparation and incubation conditions
were as stated above.
Primers and PCR amplification. Forward and reverse primers for PCR am-
plification of the DHFR genes were designed with the Primer 3 program pro-
vided by the National Center for Biotechnology Information (NCBI) (http:
//www.basic.nwu.edu/biotools/Primer3.html) based on information provided by
the ongoing The Institute for Genomic Research (TIGR) sequence program for
B. anthracis (Ames strain) (http://tigrblast.tigr.org/ufmg). These primers were
designed so that they would be positioned several bases upstream and down-
stream from the putative gene sequence for DHFR (Fig. 1). Forward and reverse
primers designed for B. anthracis DHFR were 5-CGTCCATTCCCGAAACTT
AC-3 and 5-GCATTTTCACATGCTACCTTTC-3, respectively. PCR ampli-
fication was conducted with genomic DNA extracted from B. anthracis Sterne,
using the DNeasy tissue kit, following the protocol for gram-positive bacteria
(QIAGEN), with necessary modifications. PCR products were confirmed by
separation on agarose gels, and sequence analysis of products was performed by
the Oklahoma State University DNA/Protein Resource Facility. The primers
used for sequencing were the same as those used for PCR amplification.
Construction of expression plasmid. The Invitrogen pCRT7/CT-TOPO TA
expression kit was used to construct the expression plasmid. The forward primer
for cloning into the Invitrogen pCRT7/CT-TOPO vector was designed following
the manufacturer’s specifications (Invitrogen Life Technologies). The reverse
primer was designed by removing the gene’s stop codon and adding a thrombin
cleavage site. The sequence of the forward primer was 5-AAGATGATAGTT
TCATTTATGGTCGC-3. The sequence of the reverse primer was 5-GCTGC
CGCGAGGTACTAGTTGTTGTTTCTCATATAC-3. PCR was used to am-
plify B. anthracis Sterne genomic DNA using these primers (Fig. 1). The PCR
product was then cloned into the Invitrogen pCRT7/CT-TOPO vector and trans-
formed into E. coli TOP10F chemically competent cells. Of the 10 clones picked,
restriction enzyme analysis of purified plasmid DNA showed that 8 had the insert
in the proper orientation in the vector. Plasmid DNA from these clones was
sequenced by the Oklahoma State University DNA/Protein Resource Facility
using primers included in the Invitrogen TA cloning kit. The primers were T7
forward (5-TAATACGACTCACTATAGGG-3) and V5 C-terminal reverse
(5-ACCGAGGAGAGGGTTAGGGAT-3). Plasmid DNA from a clone show-
ing the correct construct with a thrombin cleavage site was transformed into E.
coli BL21 Star (DE3)pLysS chemically competent cells for expression of the
six-histidine-tagged fusion protein.
Expression and initial purification of B. anthracis Sterne recombinant DHFR
(rDHFR). As stated above, plasmid DNA with the correct construct was trans-
formed into E. coli BL21 Star (DE3)pLysS chemically competent cells for ex-
pression of the six-histidine-tagged fusion protein, followed by purification on a
His-Bind resin column (Novagen, Inc., Madison, Wis.). The expression strain was
grown in MM/CA (21a) containing 34 g of chloramphenicol per ml and 100 g
of carbenicillin per ml at 37°C to an optical density at 600 nm of 0.6, induced with
1 mM isopropyl--D-thiogalactopyranoside (IPTG), and cultivated for 24 h at
28°C. Cells were harvested and lysed using Novagen Bug Buster protein extrac-
tion reagent with benzonase nuclease and protease inhibitory cocktail set III
(Calbiochem). Insoluble proteins were removed by centrifugation, and the sol-
uble proteins were purified by binding the His tag portion of the fusion protein
to a His-Bind (Novagen) resin column and eluted with a 5 to 500 mM imidazole
gradient in a solution of 20 mM Tris-HCl (pH 7.9) and 500 mM NaCl.
Fast-performance liquid chromatography (FPLC) purification of Sterne
rDHFR. Fractions containing B. anthracis Sterne rDHFR from the His-Bind
column were pooled and concentrated using Amicon Ultra-15 Centrifugal Filter
Devices with a 10,000-molecular-weight cutoff (Millipore Corp., Bedford, Mass.)
at 4,000 g and 4°C in a Beckman Avanti J-25 centrifuge with a JS-7.5 rotor. The
concentrated sample was desalted, and buffer was exchanged using PD 10 col-
umns (Sephadex R G-25 M) (Amersham Biosciences). Fractions were loaded
onto a high-resolution Mono-Q 5/50 GL anion exchange column (Amersham
Biosciences) and eluted in a buffer containing 20 mM Tris (pH 8.5), 1 M NaCl,
5% glycerol, and 1 mM NaN3 (elution buffer), using a gradient of 0 to 100%
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elution buffer. Two-milliliter fractions were collected. The Sterne rDHFR eluted
between 20 and 25% (i.e., 0.2 to 0.25 M NaCl).
IEF. The isoelectric point of the Sterne rDHFR was determined using Bio-
Rad Isoelectric Focusing (IEF) Ready Gels pH 3 to 10 and pH 5 to 8 under
native conditions. The gels were run with Bio-Rad IEF standards, and samples
were diluted 1:1 in IEF sample buffer (50% glycerol). Focusing was performed in
a Mini Protean 3 Cell with anode buffer (7 mM phosphoric acid) in the lower
chamber and cathode buffer (20 mM lysine and 20 mM arginine) in the upper
chamber. Gels were run under the following conditions in steps: 100 V constant
for 60 min, 250 V constant for 60 min, and 500 V constant for 30 min. Gels were
stained with Bio-Rad Crocein scarlet and Coomassie blue IEF stain for exactly
45 min followed by destaining in multiple changes of destaining solution (40%
methanol, 10% acetic acid) over a period of 2 to 3 h. Samples had been desalted
and concentrated in Amicon Ultra-4 units (Millipore) with a 10,000-molecular-
weight cutoff.
Thrombin cleavage and purification of Sterne rDHFR. The His tag was re-
moved by cleavage with 1.0 U of biotinylated thrombin (Novagen) per mg of
recombinant protein for 1 h at room temperature, followed by purification with
streptavidin agarose. B. anthracis Sterne rDHFR was stabilized throughout the
purification with 5 to 10% glycerol and stored at 80°C. Protein concentration
was determined using the Bio-Rad microassay in a 96-well format.
Molecular mass determination. Molecular mass was estimated for B. anthracis
Sterne rDHFR before and after removal of the six-histidine tag by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (12.5% poly-
acrylamide) with Novagen Perfect Protein markers. Samples and 2 Novagen
sample buffer (1:1) were heated at 95°C for 5 min prior to loading on SDS–12.5%
polyacrylamide gels. Gels were run with 200 V constant for 45 min. Gels were
stained with Coomassie brilliant blue R-250 stain and destained with 40% meth-
anol–10% acetic acid. Calculated molecular masses were determined with a
calculator program provided by the National Biomedical Research Foundation
of Georgetown University Medical Center (http://pir.georgetown.edu/pirwww
/search/comp_mw.shtml). The amino acid sequences for the gene with the His
tag cleaved and for the gene with the vector components and the His-tagged
fusion protein were entered into the calculator program, and the molecular
masses were determined.
DHFR assay. The activity for B. anthracis Sterne rDHFR was measured at
30°C as the decrease in A340 over 3 min (28). The reaction mixture (1 ml)
contained 10 mM 2-mercaptoethanol, 0.1 mM NADPH, 0.1 mM dihydrofolate,
1 mM EDTA, 50 mM potassium phosphate (pH 7), and enzyme. The reaction
was initiated by the addition of dihydrofolate after preincubation of the other
components for 3 min. For inhibition assays, various amounts of inhibitor were
added to the mixture before the 3-min preincubation period. The 50% inhibitory
concentrations (IC50s) for TMP and methotrexate were determined from a plot
of the log10 of the drug concentration versus percent inhibition using KC Junior
software. The average of two or more determinations was used. One unit of
enzyme is defined as the amount that reduces 1 mol of dihydrofolate per min
using a molar extinction coefficient of 12,300 M1 (12).
For some enzyme assays, a cell extract of E. coli BL21 Star (DE3)pLysS was
used to demonstrate the IC50 of TMP for E. coli BL21 Star (DE3)pLysS DHFR,
a bacterial strain that is sensitive to TMP (MIC of1 g/ml), as described below
in Results. The cell extract was obtained as follows. A cell pellet from a 0.5-liter
culture of E. coli BL21 Star (DE3)pLysS was treated with Bug Buster, benzonase
(Novagen), and protease inhibitor cocktail set III (Calbiochem) following the
manufacturer’s instructions. The lysate was centrifuged at 48,000 g and 4°C for
20 min and filtered through a 0.2-m-pore-size filter. The enzyme lysate was
concentrated using Amicon Ultra-15 Centrifugal Devices (Millipore) with a
10,000-molecular-weight cutoff, and buffer was exchanged to 5 mM imidazole–
0.5 M NaCl–20 mM Tris-HCl (pH 7.9). The cell extract was used in the DHFR
assay described above to determine the IC50 for TMP.
RESULTS
In vitro drug susceptibility. After the plates were incubated,
the MIC was read visually and evaluated with an optical mi-
crotiter plate reader (at 570 and 600 nm). The MICs were
compared to acceptable limits for quality control strains to
validate drug performance (19). The MIC was the lowest con-
centration of antimicrobial agent at which no color change
FIG. 1. Part of the contig obtained from the TIGR database (http://www.tigr.org) by BLAST search (BLAST hit start of 2088847 and BLAST
hit end of 2089326 contig:6611:b_anthracis). The B. anthracis DHFR gene sequence (asterisks), start and stop codons (boldface type), and the
putative Shine-Dalgarno sequence (double underline) are indicated. The locations of the left primer () and right primer (				) are
indicated.
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occurred (i.e., color remains blue). The MICs of ciprofloxacin
and doxycycline for B. anthracis Sterne were 0.25 and 0.25
g/ml, respectively. The MIC of TMP for B. anthracis Sterne
was determined to be 2,048 but 4,096 g/ml.
Transfer of resistance. Transformation of the B. anthracis
Sterne DHFR gene into E. coli BL21 Star (DE3)pLysS and
subsequent MIC evaluation using the AlamarBlue broth dilu-
tion assay demonstrated a change in the MIC of TMP from1
g/ml for the wild-type E. coli BL21 Star (DE3)pLysS to
2,048 but 4,096 g/ml for the E. coli BL21 Star
(DE3)pLysS containing the Sterne DHFR construct. The MIC
of TMP for E. coli BL21 Star (DE3)pLysS, transformed with
the vector only, was 1.0 g/ml. This was equivalent to the
TMP MIC obtained with the AlamarBlue broth dilution assay
using B. anthracis Sterne as the test organism. A protein-
protein BLAST search with the B. anthracis Sterne DHFR
demonstrated that the B. anthracis virulence plasmids pX01
(NC003980) and pX02 (NC4003981), sequenced by NCBI, do
not contain DHFR genes. Therefore, these results suggest that
the basis for TMP resistance is located on the chromosome.
Deduced sequence of DHFR gene from B. anthracis Sterne.
A BLAST search of the TIGR Genome Sequencing project
(http://www.tigr.org), using NCBI accession number NP
656101 resulted in the contig sequence presented in Fig. 1.
Primers (described above) were designed using the Primer3
program provided by the Whitehead Institute for Biomedical
Research (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi)
(Fig. 1). The NCBI ORF Finder was then used to determine
the open reading frame (ORF) of the putative DHFR (Fig. 2)
(http://www.ncbi.nlm.nih.gov/gorf/gorf.html) (Fig. 1). A BLAST
search of NCBI with the ORF information was used to confirm
the putative sequences, and the Shine-Dalgarno sequence was
deduced (24).
Transformation, expression, and purification. Sequence
analysis of plasmid DNA from two clones of E. coli TOP10F
transformed with pCRT7/CT-TOPO-Sterne DHFR showed
the correct construct including the thrombin cleavage site. A
pilot expression experiment was performed by transforming E.
coli BL21 Star (DE3)pLysS competent cells with plasmid DNA
from one of the clones and growing the organism in MM/CA
with 34 g of chloramphenicol per ml and 100 g of carben-
icillin per ml. E. coli BL21 Star (DE3)pLysS competent cells
was transformed with plasmid DNA containing only the
pCRT7/CT-TOPO vector to compare B. anthracis Sterne
DHFR expression and enzyme activity to that of endogenous
E. coli BL21 Star (DE3)pLysS enzyme. Cultures were grown at
37°C with shaking at 200 rpm until the bacteria were induced
with 1 mM IPTG. When the bacteria were induced with IPTG,
incubation conditions were changed to 28°C and 200 rpm for
24 h. Samples were taken at the appropriate times for lysis and
protein evaluation. After 24 h, cultures were harvested by
centrifugation at 10,000  g and 4°C for 20 min, the superna-
tants were removed, and the pellets were frozen at 80°C.
Pellets were lysed with Bug Buster (Novagen), benzonase nu-
clease (Novagen), and protease inhibitor cocktail III (Calbio-
chem). The gel analysis showed good expression of Sterne
rDHFR and little expression of endogenous DHFR (Fig. 3).
B. anthracis Sterne rDHFR expression on a large scale was
studied as follows. Cells were grown in 0.5 liter of MM/CA
containing 34 g of chloramphenicol per ml, 100 g of car-
benicillin per ml, and 1 mM IPTG for induction. Cells were
grown at 28°C for 24 h. Cells were harvested by centrifugation
and lysed with Bug Buster (Novagen) as usual. Soluble His-
tagged Sterne rDHFR was initially purified using His-Bind
resin (Novagen) with elution using a 5 to 500 mM imidazole
gradient. SDS-PAGE analysis of eluted fractions indicated
those fractions which contained six-histidine-tagged Sterne
rDHFR. Those fractions were pooled, concentrated, and de-
salted, and buffer was exchanged to 20 mM Tris-HCl (pH
8.5)–5% glycerol. Samples were loaded onto a Mono-Q col-
FIG. 2. ORF obtained with ORF Finder (NCBI) using the contig
presented in Fig. 1. Start and stop codons are shown in boldface type.
FIG. 3. SDS–12.5% polyacrylamide gel showing steps involved in
purification of B. anthracis Sterne rDHFR. Lanes 1 and 6 contain
Novagen Perfect Protein markers (15 to 150 kDa ladder). Lane 2
contains cell lysate from E. coli BL21 Star (DE3) carrying plasmids
pLysS and pCRT7/CT-TOPO-Sterne rDHFR with the six-histidine tag
(precolumn) (lysate filtered through a 0.22-m-pore-size filter). Lane
3 contains pooled Sterne rDHFR with the six-His tag (enzyme purified
by passage through a nickel column). Lane 4 contains FPLC-purified
Sterne rDHFR with the six-His tag, and lane 5 contains FPLC-purified
Sterne rDHFR with the six-His tag removed.
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umn and eluted with a 0 to 100% gradient of solution consist-
ing of 1 M NaCl, 20 mM Tris-HCl (pH 8.5), and 5% glycerol.
In order to optimize Mono-Q purification, the isoelectric
point of the recombinant fusion protein was determined to be
7.1. Once optimum conditions were determined, a purification
protocol for Sterne rDHFR was established. This protocol
consisted of prepurification with the His-Bind column, fol-
lowed by final purification using the Mono-Q column. For
some enzyme assays, the histidine tag was cleaved, and the
resulting rDHFR was purified as described in Materials and
Methods. The isoelectric point of the cleaved protein (Sterne
DHFR with the six-histidine tag removed) is 5.5.
Molecular mass determination. SDS-PAGE with Novagen
Perfect Protein markers showed that the molecular masses of
Sterne rDHFR with the six-histidine tag and Sterne rDHFR
with the histidine tag cleaved were 23.5 and 21.5 kDa, respec-
tively (Fig. 3). The calculated molecular masses were 23 and
19.6 kDa, respectively.
Enzyme functionality. Enzyme assays demonstrated that the
B. anthracis Sterne rDHFR had high enzyme activity, while the
lysate from the construct with only the vector had very little
activity (Table 1).
IC50. The mean IC50s of TMP and methotrexate for Sterne
rDHFR with the histidine tag were determined to be 77,324
and 15.06 nM, respectively. With the His tag removed, the
IC50s were determined to be 77,233 and 12.21 nM, respec-
tively. Purified Mycobacterium avium rDHFR was used as a
reference, since that organism is also naturally resistant to
TMP (Table 1) (28). The IC50s of TMP and methotrexate for
M. avium rDHFR were 5,752 and 5.10 nM, respectively (Table
1). Methotrexate, a potent inhibitor of DHFR, including hu-
man DHFR (27), was used as a positive control. The mean
IC50 of TMP for the E. coli BL21 Star (DE3)pLysS DHFR was
determined to be 0.63 nM (standard error of the mean 

0.078; n 
 3).
Homology. Alignment of the B. anthracis Sterne DHFR
(GenBank accession number AY569129) amino acid sequence
revealed 100% homology with various virulent strains that
are being sequenced by TIGR (http://www.tigr.org/tdb/mdb
/mdbinprogress.html), including Ames, Western N. America
(GT3 Group A1a), and Kruger B (GT87 Group B1) (Fig. 4). B.
anthracis Sterne DHFR showed 98% identity with Bacillus
cereus ATCC 14579 DHFR (NCBI accession number
NP_831957) (15). B. anthracis Sterne DHFR showed 55%
identity with Bacillus subtilis DHFR (NCBI accession number
AAA22853) (16) (Fig. 4). B. anthracis Sterne DHFR showed
33% identity with M. avium DHFR (NCBI accession number
AF006616) (28) (Fig. 4), which is also naturally resistant to
TMP.
DISCUSSION
Logical drug design requires an appropriate target (e.g.,
enzyme) and a means by which that target can be evaluated for
optimum development of an effective antimicrobial agent. In
that regard, for enzyme targets, recombinant enzyme is essen-
tial, not only for in vitro assessment of test compounds but also
for eventual molecular modeling involving crystallography.
Evaluation of the literature revealed that B. anthracis is natu-
rally resistant to an antimicrobial agent that has been shown to
be effective against various other bacterial pathogens (20).
That antimicrobial is TMP (20), a synthetic drug that targets an
enzyme in the folate biosynthetic pathway, DHFR.
Since TMP was introduced for clinical use in 1969, a variety
of TMP-resistant bacteria have been isolated (7). The inhibi-
tory effects of TMP are associated with its ability to inhibit
DHFR, a key enzyme in the folate biosynthetic pathway (11).
As a result of TMP’s inhibitory abilities, intracellular reduced
folates are depleted and one-carbon transfer reactions are
limited (11). This eventually affects RNA, DNA, and protein
synthesis (11). Resistance to TMP is generally seen as the
production of an extra DHFR found on plasmids or other
genetic elements (5, 9, 13). In addition, TMP resistance can
result from mutations in the chromosomal gene that result in a
higher Ki for the drug (1, 8, 13, 17, 21), as well as the produc-
tion of an additional DHFR (7). Development of high MICs
has been associated with a combination of a structurally mod-
ified enzyme and overproduction (10).
If natural resistance to TMP is due to the lack of selectivity
for the B. anthracis DHFR, then that enzyme target might
prove useful as a candidate for the development of antimicro-
bial agents that would presumably not be in the standard an-
timicrobial armamentarium. However, potentially useful drugs
might be available in existing chemical libraries and prove to be
advantageous for the development of more effective inhibitors
for B. anthracis.
One purpose of this study was to confirm the in vitro resis-
tance of B. anthracis to TMP. Another objective was to clone
and express recombinant B. anthracis Sterne DHFR and use it
to demonstrate that resistance to TMP is due to the lack of
selectivity for the enzyme. With this information, it should be
possible to screen stockpiled antifolates to identify potential
narrow-spectrum drugs that would selectively affect B. anthra-
cis DHFR. rDHFR would also be important for screening
purposes and for design and synthesis of new narrow-spectrum
inhibitors of B. anthracis.
Zywno-van Ginkel et al. previously reported the identifica-
tion and functional cloning of M. avium DHFR (NCBI acces-
sion number AF006616) (28), which is also naturally resistant
to TMP (26). Suling et al. performed an initial screening with
recombinant DHFR, which eventually led to a lead compound
that showed selective activity against M. avium rDHFR (26).
As discussed in that study, use of the rDHFR was essential in
determining a logical progression in the synthesis of improved
inhibitors. It is possible that a similar effort is possible with the
DHFR from B. anthracis.
TABLE 1. IC50 data for four rDHFRs
Enzyme
IC50 (nM)a
TMP MTXb
Human rDHFR 1.62  106  5.77  103 (2) 24.3  6.99 (3)
B. anthracis Sterne
rDHFR
With His tag 7.73  104  8.24  103 (4) 15.1  2.82 (3)
Without His tag 7.72  104  2.04  103 (4) 12.2  3.1 (3)
M. avium rDHFR 5.75 103  7.70  102 (3) 5.1  0.83 (5)
a Each value is the mean  standard error of the mean. The number of
samples is given in parentheses.
b MTX, methotrexate.
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Examination of the sequence information for B. anthracis
Ames (NCBI accession number NP_844628) (22) and B. an-
thracis Sterne reveals a 100% homology for the amino acid
sequences of the two strains for DHFR [E.C. 1.5.1.3]. In ad-
dition, a BLAST search of these amino acid sequences against
B. anthracis A2012 (NCBI accession number NP_656101) (23)
(data not shown) as well as the Kruger strain (TIGR Microbial
Genome project) revealed 100% homology for DHFR. This is
important because the Kruger strain originated from the
Kruger National Park in South Africa, the area that reported
100% resistance against TMP and 95% resistance for various
sulfonamides (20). Thus, the recombinant product produced
from the DHFR sequence of the Sterne strain can be used for
in vitro drug screening for all the reported virulent strains of B.
anthracis.
Using standard procedures, we were able to clone and ex-
press the chromosomally encoded gene for DHFR in B. an-
thracis. In vitro assays with B. anthracis Sterne showed a high
level of resistance against TMP (2,048 but 4,096 g/ml).
Previously, others have reported a high level of TMP resistance
for a clinical isolate of E. coli; the MIC was1 g/liter (10). The
resistance of that particular isolate was due to overproduction
of DHFR as a result of a promoter up-mutation (10). Resis-
tance to TMP due to mutations in the DHFR chromosomal
gene has been reported for the gram-positive Streptococcus
pneumoniae (1). The MICs reported in that study ranged from
FIG. 4. Alignment of the B. anthracis Sterne DHFR sequence (GenBank accession number AY569129) (BanthSterne) with the DHFR
sequences from B. anthracis Ames, Western N. America GT3 Group A1a (West), and Kruger B GT87 Group B1 (Kruger) and from B. cereus
(Bcer), B. subtilis (Bsubt), and M. avium (Mavium). Identical residues are shown as white letters on black background. Alignment was accomplished
with MacVector 7 (Accelrys, San Diego, Calif.). Gaps introduced to maximize alignment are shown as dashes.
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64 to 512 g/ml and were due to two main groups of mutations
both sharing six amino acid changes (1).
In our study, the enzyme assay established an IC50 of 77,233
nM for the Sterne rDHFR when tested with TMP, thus dem-
onstrating a reduced selectivity for the target. By comparison,
the IC50 for methotrexate, a potent inhibitor of most DHFRs,
including human DHFR (27), was observed to be 12.21 nM.
These results help to clarify the reason for TMP resistance in
B. anthracis. With this information, it will be possible to con-
duct appropriate screening of potential inhibitors from chem-
ical stockpiles. Once inhibitors are identified, further drug
development can continue, making it possible to obtain nar-
row-spectrum inhibitors for treatment of anthrax. In that re-
gard, recombinant product will also be important for crystal-
lographic studies that will be essential for designing new
inhibitors.
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